RxDoctor Payments Data

Hanna Dgheim, MD

Internal Medicine · Nanuet, NYNPI 1184710030

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 54 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$225
  • AstraZeneca$199
  • Calliditas Therapeutics US Inc.$129
  • Merck$86
  • Amarin Pharma, Inc.$81
  • Boehringer Ingelheim$73
  • plus $475 from 14 others

What the payments were for

  • Food & beverage$1,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,268 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$331,062
Medicare patients
417
Services billed
1,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol179$131,766
JanuviaSitagliptin Phosphate105$100,847
EliquisApixaban137$89,536
OzempicSemaglutide39$66,800
JardianceEmpagliflozin52$37,462
MounjaroTirzepatide26$34,619
VascepaIcosapent Ethyl34$22,568
KerendiaFinerenone28$19,885
LokelmaSodium Zirconium Cyclosilicate19$14,472
MyrbetriqMirabegron21$13,521
Soliqua 100-33Insulin Glargine/Lixisenatide13$12,046
Breo ElliptaFluticasone/Vilanterol18$9,707
ProsolParenteral Amino Acid 20% No.152$9,332
TrulicityDulaglutide11$9,178
Sevelamer Carbonate73$8,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere$199$154,572212 claims
MerckJanuvia$86$100,847105 claims
PfizerEliquis$45$89,536137 claims
Novo NordiskOzempic$33$66,80039 claims
Boehringer IngelheimJardiance$73$37,46252 claims
BayerKerendia$225$19,88528 claims
Astellas Pharma US IncMyrbetriq$16$13,52121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Nanuet

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →